I would not do it for OS, but the other parameters are quite interesting...
Hormone therapy is a highly effective treatment for prostate cancer; however, it is known to cause metabolic side effects like weight gain and insulin resistance, increasing the risk of other health problems like diabetes, heart disease, and stroke.
The STAMPEDE trial, with nearly 12,000 participants, is the world’s largest interventional prostate cancer trial. This study involved 1,874 men with metastatic prostate cancer who did not have diabetes. The men were divided into two groups, with one group receiving standard treatment and the other receiving standard treatment plus metformin.
The results showed that:
● After two years, men who took metformin gained only half as much weight (2kg) compared to those who received standard treatment alone.
● The metformin group also had lower blood sugar levels and lower levels of harmful circulating fats, including cholesterol.
● There were significantly fewer reports of metabolic syndrome, a cluster of health problems that increase the risk of type 2 diabetes and heart disease, in the metformin group.
● Individuals taking metformin had a 10% lower risk of dying and lived for around six months longer than those receiving standard treatment only. This effect was particularly notable in men with more advanced forms of prostate cancer.
Professor Noel Clarke, a consultant urologist and one of the principal investigators of the trial, believes that this new indication for metformin will soon be available on the NHS, allowing more patients to benefit.
While these findings are preliminary and require further research to confirm their implications, they offer hope for men with advanced prostate cancer. Metformin’s potential to reduce the side effects of hormone therapy and potentially improve survival rates could significantly improve the lives of countless men battling this disease.